🇺🇸 FDA
Pipeline program

EDG-5506

EDG-5506-104

Phase 1 small_molecule completed

Quick answer

EDG-5506 for Muscular Dystrophies is a Phase 1 program (small_molecule) at Edgewise Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Edgewise Therapeutics
Indication
Muscular Dystrophies
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials